# Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

> **NCT03506997** · PHASE2 · UNKNOWN · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 100 (estimated)

## Conditions studied

- Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03506997
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-27
- **Primary completion:** 2023-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03506997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03506997, "Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03506997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*